Wiener klinische Wochenschrift

, Volume 127, Issue 1–2, pp 12–15 | Cite as

10th anniversary of the Austrian MDS Platform: aims and ongoing projects

  • Sonja BurgstallerEmail author
  • Peter Bettelheim
  • Otto Krieger
  • Sigrid Machherndl-Spandl
  • Thomas Nösslinger
  • Lisa Pleyer
  • Heinz Sill
  • Wolfgang R. Sperr
  • Reinhard Stauder
  • Peter Valent
  • Michael Pfeilstöcker
review article


The Austrian myelodysplastic syndromes (MDS) Platform was founded as a national working group in 2003 to initiate and coordinate common projects in the field. The incidence of MDS in Austria is approximately 400–500 new MDS cases per year. The overall low number of MDS patients underlines the importance of a national initiative to concentrate knowledge at certain specialized centres, where treatment of these patients mainly takes place. Clinical trials as well as basic research are facilitated by the cooperation of university and non-university hospitals. Other objectives are the generation of therapeutic standards, organization of meetings to spread this information to physicians and patients as well as promoting patient-support groups. Cooperation with international working groups is another important aim of the Platform. The 10th anniversary of the Austrian MDS Platform was organized as a meeting for all interested physicians throughout Austria providing an update on the disease and ongoing projects.


MDS Austrian platform meeting 10th anniversary 

10 Jahre MDS Plattform – Ziele und Projekte


Die österreichische MDS Plattform wurde 2003 mit dem Ziel gegründet, wissenschaftliche Aktivitäten wie klinische Forschung und Grundlagenforschung durchzuführen, Therapiestandards zu erstellen und Fortbildungsveranstaltungen zu organisieren sowie Patientenselbsthilfegruppen zu unterstützen. Durch die Zusammenarbeit innerhalb der Plattform konnten viele Ziele in den letzten 10 Jahren erreicht werden. Das 10-Jahres Jubiläum wurde als Veranstaltung für alle interessierten Ärzte/Ärztinnen in Österreich gestaltet, um ein Update über die Erkrankung sowie die laufenden Projekte der Plattform zu bieten.


MDS Österreichisches Plattformtreffen 10-Jahres Jubiläum 


Conflict of interest

S. B., Honoraria Celgene, Novartis, AOP; P. B.; O. K.; S. M. had no conflict of interest; T. N., advisory board: Celgene; L. P., Honoraria Celgene; H. S. had no conflict of interest; W. S., Honoraria Celgene, Novartis, Ariad; R. S., research support: Celgene, Teva, Honoraria Celgene, Teva, Novartis, scientific advisory board Celgene; P. V., Honoraria Celgene; M. P., Honararia Celgene, Novartis.


  1. 1.
    Bennet JM, Catovsky D, Daniel MT, Flandrin G, Galton DA, Gralnick HR, et al. Proposals for the classification of the myelodysplastic syndromes. Br J Haematol. 1982;51:189–99.CrossRefGoogle Scholar
  2. 2.
    Vardiman JW, Thiele J, Arber DA, Brunning RD, Borowitz MJ, Porwit A, et al. The 2008 revision of the World Health Organization (WHO) classification of myeloid neoplasms and acute leukemia: rationale and important changes. Blood. 2009;114:937–51.PubMedCrossRefGoogle Scholar
  3. 3.
    Sill H, Olipitz W, Zebisch A, Schulz E, Wölfler A. Therapy-related myeloid neoplasms: pathobiology and clinical characteristics. Br J Pharmacol. 2011;162:792–805.PubMedCentralPubMedCrossRefGoogle Scholar
  4. 4.
    Valent P, Horny HP, Bennet JM, Fonatsch C, Germing U, Greenberg P, et al. Definitions and standards in the diagnosis and treatment of the myelodysplastic syndromes: consensus statements and report from a working conference. Leuk Res. 2007;31:727–36.PubMedCrossRefGoogle Scholar
  5. 5.
    Westers TM, Ireland R, Kern W, Alhan C, Balleisen JS, Bettelheim P, et al. Standardization of flow cytometry in myelodysplastic syndromes: a report from an international consortium and the European LeukemiaNet Working Group. Leukemia. 2012;26:1730–41.PubMedCrossRefGoogle Scholar
  6. 6.
    Greenberg P, Cox C, LeBeau MM, Fenaux P, Morel P, Sanz M, et al. International scoring system for evaluating prognosis in myelodysplastic sydromes. Blood. 1997;89:2079–88.PubMedGoogle Scholar
  7. 7.
    Greenberg P, Tuechler H, Schanz J, Sanz G, Garcia-Manero G, Solé F, et al. Revised international prognostic scoring system for myelodysplastic syndromes. Blood. 2012;120:2454–65.PubMedCrossRefGoogle Scholar
  8. 8.
    Nösslinger T, Tüchler H, Germing U, Sperr WR, Krieger O, Haase D, et al. Prognostic impact of age and gender in 897 untreated patients with primary myelodysplastic syndromes. Ann Oncol. 2010;21:120–5.PubMedCrossRefGoogle Scholar
  9. 9.
    Stauder R, Nösslinger T, Pfeilstöcker M, Sperr WR, Wimazal F, Krieger O, et al. Impact of age and comorbidity in myelodysplastic syndromes. J Natl Compr Canc Netw. 2008;9:927–34.Google Scholar
  10. 10.
    Sperr WR, Wimazal F, Kundi M, Baumgartner C, Nösslinger T, Makrai A, et al. Comorbidity as prognostic variable in MDS: comparative evaluation of the HCT-CI and CCI in a core dataset of 419 patients of the Austrian MDS Study Group. Ann Oncol. 2010;21:114–9.PubMedCrossRefGoogle Scholar
  11. 11.
    Zipperer E, Pelz D, Nachtkamp K, Kuendgen A, Strupp C, Gattermann N, et al. The hematopoietic stem cell transplantation comorbidity index is of prognostic relevance for patients with myelodysplastic syndrome. Haematologica. 2009;94:729–32.PubMedCentralPubMedCrossRefGoogle Scholar
  12. 12.
    Charlson ME, Pompei P, Ales KL, MacKenzie CR. A new method of classifying prognostic comorbidity in longitudinal studies: development and validation. J Chronic Dis. 1987;40:373–83.PubMedCrossRefGoogle Scholar
  13. 13.
    Sorror ML, Maris MB, Baron F, Sandmaier BM, Maloney DG, Storer B. Hematopoietic Cell Transplantation (HCT)-Specific Comorbidity Index: a new tool for risk assessment before allogeneic HCT. Blood. 2005;106:2912–9.PubMedCentralPubMedCrossRefGoogle Scholar
  14. 14.
    Sperr WR, Kundi M, Wimazal F, Nösslinger T, Schönmetzler-Makrai A, Stauder R, et al. Proposed score for survival of patients with myelodysplastic syndromes. Eur J Clin Invest. 2013;43:1120–8.PubMedGoogle Scholar
  15. 15.
    Bammer C, Sperr WR, Kemmler G, Wimazal F, Nösslinger T, Schönmetzler A, et al. Clustering of comorbidities is related to age and sex and impacts clinical outcome in myelodysplastic syndromes. J Geriatr Oncol. 1879;4068(14):299–306. doi:10.1016/j.jgo.2014.02.002Google Scholar
  16. 16.
    Hamaker ME, Prins MC, Stauder R. The relevance of a geriatric assessment for elderly patients with a haematologic malignancy—a systematic review. Leuk Res. 2014;38:275–83.PubMedCrossRefGoogle Scholar
  17. 17.
    Stauder R. The challenge of personalized risk assessment and therapy planning in elderly high-risk myelodysplastic syndromes (MDS) patients. Ann Haematol. 2012;91:1333–43.CrossRefGoogle Scholar
  18. 18.
    Stauder R, Wimazal F, Nösslinger T, Krieger O, Sperr WR, Sill H, et al. Individualized management and therapy of myelodysplastic syndromes. Wien Klin Wochenschr. 2008;120:523–37.PubMedCrossRefGoogle Scholar
  19. 19.
    Greenberg PL, Sun Z, Miller KB, Bennett JM, Tallman MS, Dewald G, et al. Treatment of myelodysplastic syndrome patients with erythropoietin with or without granulocyte colony-stimulating factor: results of a prospective randomized phase 3 trial by the Eastern Cooperative Oncology Group (E1996). Blood. 2009;114:2393–400.PubMedCentralPubMedCrossRefGoogle Scholar
  20. 20.
    Hellstrom-Lindberg E, Gulbrandsen N, Lindberg G, Ahlgren T, Dahl IM, Dybedal I, et al. Scandinavian MDS group. A validated decision model for treating the anaemia of myelodysplatic syndromes with erythropoietin + granulocyte colony-stimulating factor: significant effects on quality of life. Br J Haematol. 2003;120:1037–46.PubMedCrossRefGoogle Scholar
  21. 21.
    Valent P, Krieger O, Stauder R, Wimazal F, Nösslinger T, Sperr WR, et al. Iron overload in myelodysplastic syndromes (MDS)—diagnosis, management, and response criteria: a proposal of the Austrian MDS Platform. Eur J Clin Invest. 2008;38:143–9.PubMedCentralPubMedCrossRefGoogle Scholar
  22. 22.
    Haase D, Germing U, Schanz J, Pfeilstöcker M, Nösslinger T, Hildebrandt B, et al. New insights into the prognostic impact of the karyotype in MDS and correlation with subtypes: evidence from a core dataset of 2124 patients. Blood. 2007;110:4385–95.PubMedCrossRefGoogle Scholar
  23. 23.
    Fenaux P, Giagounidis A, Sellelag D, Beyne-Rauzy O, Mufti G, Mittelman M, et al. A randomized phase 3 study of lenalidomide versus placebo in RBC transfusion-dependent patients with low-/intermediate-1-risk myelodysplastic syndromes with del5q. Blood. 2011;118:3765–76.PubMedCrossRefGoogle Scholar
  24. 24.
    List A, Dewald G, Bennet J, Giagounidis A, Raza A, Feldman E, et al. Lenalidomide in the myelodysplastic syndrome with chromosome 5q deletion. N Engl J Med. 2006;355:456–65.CrossRefGoogle Scholar
  25. 25.
    Cutler CS, Lee SJ, Greenberg P, Deeg HJ, Pérez WS, Anasetti C, et al. A decision analysis of allogeneic bone marrow transplantation for the myelodysplastic syndromes: delayed transplantation for low-risk myelodysplasia is associated with improved outcome. Blood. 2004;104:579–85.PubMedCrossRefGoogle Scholar
  26. 26.
    Fenaux P, Mufti GJ, Hellstrom-Lindberg E, Santini V, Finelli C, Giagounidis A, et al. Efficacy of azacitidine compared with that of conventional care regimens in the treatment of higher risk myelodysplastic syndromes: a randomised, open-label phase III study. Lancet Oncol. 2009;10:223–32.PubMedCentralPubMedCrossRefGoogle Scholar
  27. 27.
    Prébet T, Gore DS, Esterni B, Gardin C, Itzykson R, Thepot S, et al. Outcome of high-risk myelodysplastic syndrome after azacitidine treatment failure. J Clin Oncol. 2011;29:475–83.CrossRefGoogle Scholar
  28. 28.
    Pleyer L, Stauder R, Thaler J, Ludwig H, Pfeilstöcker M, Steinkirchner S, et al. Overall survival data of patients with MDS, AML and CMML from the Austrian Azacitidine Registry of 184 consecutive patients. Leuk Res. 2011;35(Suppl 1):450.Google Scholar
  29. 29.
    Pleyer L, Germing U, Sperr WR, Linkesch W, Burgstaller S, Stauder R, et al. Azacitidine in CMML: matched-pair analyses of daily-life patients reveal modest effects on clinical course and survival. Leuk Res. 2014;38:475–83.PubMedCrossRefGoogle Scholar
  30. 30.

Copyright information

© Springer-Verlag Wien 2014

Authors and Affiliations

  • Sonja Burgstaller
    • 1
    Email author
  • Peter Bettelheim
    • 2
  • Otto Krieger
    • 2
  • Sigrid Machherndl-Spandl
    • 2
  • Thomas Nösslinger
    • 3
    • 4
  • Lisa Pleyer
    • 5
  • Heinz Sill
    • 6
  • Wolfgang R. Sperr
    • 7
  • Reinhard Stauder
    • 8
  • Peter Valent
    • 7
    • 4
  • Michael Pfeilstöcker
    • 3
    • 4
  1. 1.Department of Internal Medicine IVKlinikum Wels-GrieskirchenWelsAustria
  2. 2.Department of Internal Medicine IKrankenhaus der ElisabethinenLinzAustria
  3. 3.3rd Department or Hematology and OncologyHanusch HospitalViennaAustria
  4. 4.Ludwig-Boltzmann Cluster OncolgyMedical University of ViennaViennaAustria
  5. 5.3rd Medical Department with Hematology and Medical Oncology, Hemostaseology, Rheumatology and Infectiology, Laboratory for Immunological and Molecular Cancer ResearchParacelsus Medical University Hospital SalzburgSalzburgAustria
  6. 6.Department of Internal Medicine, Division of HematologyMedical University GrazGrazAustria
  7. 7.Department of Internal Medicine I, Division of Hematology and HemostaseologyMedical University of ViennaViennaAustria
  8. 8.Department of Internal Medicine V (Hematology and Oncology)Innsbruck Medical UniversityInnsbruckAustria

Personalised recommendations